Physician profile
Peng Wang
NPI 1679801435
$8,209.62
in general payments reported to CMS, 2019-2025
12 companies · $4,597 in 2025
The $4,597 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $1,600 · 2022: $1,607 · 2023: $92.97 · 2025: $4,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,972 · Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,971.60 |
| Food and Beverage | $718.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $4,278.66 | 2025 | |
| Pfizer INC. | $1,706.54 | 2020-2022 | |
| Aveo Pharmaceuticals, INC. | $1,500.00 | 2022 | |
| Dendreon Pharmaceuticals LLC | $318.62 | 2025 | Provenge |
| Janssen Biotech, INC. | $115.69 | 2019 | |
| Merck Sharp & Dohme LLC | $101.31 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $92.97 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $82.79 | 2019 | |
| Array Biopharma INC | $13.04 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peng Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.